Dr Emma Davenport | Group Leader

Davenport, Emma

Emma Davenport's research focuses on integrating functional genomics and clinical data in order to understand how genetics contributes to the patient-to-patient heterogeneity in treatment response.

Emma is interested in why there can be such variability between individuals with a disease and in response to treatment. She uses gene expression data to identify subgroup specific signatures and to map in vivo expression quantitative trait locus (eQTL) interactions. eQTL interactions occur when an eQTL effect is modulated by an environmental perturbation such as treatment with a drug. We hypothesise that identifying such interactions will help identify context specific regulators such as transcription factors and key pathways which will give insights into disease and drug mechanisms of action.

Emma conducted her postdoctoral research in Professor Soumya Raychaudhuri’s lab at Brigham and Women’s Hospital, Harvard Medical School and the Broad Institute. There she developed a statistical framework to investigate how the administration of a drug alters the relationship between genomic variation and gene expression (drug eQTL interactions).

Emma completed her PhD research under the supervision of Professor Julian Knight at the University of Oxford. She investigated the genetic determinants of variation in the human response to common and rare infection, focusing on sepsis and common variable immunodeficiency disorders. A key finding was a gene expression signature stratifying patients into two distinct sepsis response signature (SRS) groups. The SRS1 group identifies individuals with an immunosuppressed phenotype and was associated with higher mortality.

Publications

  • Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial.

    Davenport EE, Amariuta T, Gutierrez-Arcelus M, Slowikowski K, Westra HJ et al.

    Genome biology 2018;19;1;168

  • Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

    Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC et al.

    American journal of respiratory and critical care medicine 2017;196;3;328-339

  • Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.

    Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P et al.

    The Lancet. Respiratory medicine 2016;4;4;259-71

  • Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders.

    van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B et al.

    Clinical immunology (Orlando, Fla.) 2015;160;2;301-14

  • Transcriptomic profiling facilitates classification of response to influenza challenge.

    Davenport EE, Antrobus RD, Lillie PJ, Gilbert S and Knight JC

    Journal of molecular medicine (Berlin, Germany) 2015;93;1;105-14

  • Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial.

    Davenport EE, Amariuta T, Gutierrez-Arcelus M, Slowikowski K, Westra HJ et al.

    Genome biology 2018;19;1;168

  • A community approach to mortality prediction in sepsis via gene expression analysis.

    Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA et al.

    Nature communications 2018;9;1;694

  • Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study.

    Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE et al.

    The Lancet. Respiratory medicine 2017;5;10;816-826

  • Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

    Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC et al.

    American journal of respiratory and critical care medicine 2017;196;3;328-339

  • Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.

    Dhalla F, Fox H, Davenport EE, Sadler R, Anzilotti C et al.

    Clinical and experimental immunology 2016;184;2;216-27

  • Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.

    Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P et al.

    The Lancet. Respiratory medicine 2016;4;4;259-71

  • Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders.

    van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B et al.

    Clinical immunology (Orlando, Fla.) 2015;160;2;301-14

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

    Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB et al.

    Nature genetics 2015;47;7;717-726

  • Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.

    Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M et al.

    The Lancet. Respiratory medicine 2015;3;1;53-60

  • Transcriptomic profiling facilitates classification of response to influenza challenge.

    Davenport EE, Antrobus RD, Lillie PJ, Gilbert S and Knight JC

    Journal of molecular medicine (Berlin, Germany) 2015;93;1;105-14

  • A common haplotype of the TNF receptor 2 gene modulates endotoxin tolerance.

    Fairfax BP, Davenport EE, Makino S, Hill AV, Vannberg FO and Knight JC

    Journal of immunology (Baltimore, Md. : 1950) 2011;186;5;3058-65

Davenport, Emma
Emma's Timeline
2018

Joined Sanger Institute (Group Leader)

2015

Started Postdoctoral Fellowship, Raychaudhuri Group, Harvard Medical School

2010

Started DPhil in Clinical Medicine, J Knight Group, University of Oxford

2006

Started MBiochem in Molecular and Cellular Biochemistry, University of Oxford